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ABSTRACT 
Objective: To evaluate and compare the in-vitro dissolution profiles of five generic immediate release (IR) products of Meloxicam (MX) available in 
Egyptian market with the innovator reference product (Mobic®
Results: The study showed that two generic products, out of five, gave similar dissolution profiles with R using a specified well controlled condition 
of FTC. A selected generic product (Mobitil, G1) was tested versus R under different operational conditions of the FTC such as cell size, type of flow, 
tablet position and open & closed loops setup. The dissolution profile of MX from R was highly affected by changing the tablet position, slightly 
affected by the open & closed loops setup and not affected by cell size and type of flow. On the other hand, the dissolution profile of MX from G1 was 
affected by all the previous operational conditions. Comparing ƒ
, R) using different operational conditions of the flow through dissolution cell (FTC, 
USP Apparatus 4), in phosphate buffer (pH=7.5).  
Methods: The comparative in-vitro dissolution studies were performed under different FTC operational conditions such as cell size, tablet position 
within the cell, open and closed loops setup and type of flow (laminar and turbulent) on MX dissolution rate from different IR products.  
2  values between G1 against R among the different operational conditions proposed, 
only one in-vitro dissolution test showed similar dissolution profile of G1 with respect to R. 
Conclusion: Three generic products of MX might not be interchangeable with the innovator product (Mobic®




Sensitive and reproducible dissolution data derived from 
physicochemically and hydrodynamically defined conditions are 
necessary in order to compare variability and reproducibility in in-
vitro dissolution data and to be able to use such results as a 
surrogate for possible in-vivo bioavailability, bioequivalelence 
testing and in-vitro / in-vivo correlations (IVIVC) [1-3]. With respect 
to the IVIVC concept, in-vitro (mainly dissolution) tests are applied 
as a tool to predict drug product performance in-vivo [1,4]. 
The dissolution test is an empirical in-vitro test used to quantify the 
dissolution rate of an active pharmaceutical ingredient (API) from a 
dosage form into solution. Dissolution testing is used throughout the 
life cycle of pharmaceutical dosage forms, from feasibility studies in 
formulation development to quality control in manufacturing [5,6].  
After the development of a generic product, a pivotal bioequivalence 
study should be carried out according to reference guidelines (FDA, 
EMEA, and WHO). The in-vitro dissolution study data of the bio batch 
will be the measure of product performance. Acceptable products 
are bioequivalent, whereas unacceptable products might be bio-in-
equivalent. To achieve an IVIVC, at least three batches, that are differ 
in both in-vivo and in-vitro performance, should be available. If 
batches show differences in bioavailability, then the in-vitro test 
conditions can be modified to achieve the required IVIVC.  
The in-vitro dissolution curve is usually determined by a suitable 
dissolution test, and the in-vivo absorption curve is frequently 
determined by deconvolution using model-dependent (e. g., Wagner-
Nelson or Loo-Riegelman) [7] or direct mathematical deconvolution 
[8]. Developing an in-vitro dissolution test that gives a 1:1 IVIVC for a 
particular drug product is an important objective to facilitate 
product development and serves as a quality control procedure 
during product manufacture. Drug manufacturers typically use such 
tests to assess lot-to-lot variability and product shelf life and to 
predict in-vivo performance (i. e., bioavailability) with reasonable 
assurance after conducting minor formulation and process changes 
[9]. In the absence of a suitable in-vitro test that can be interpolated 
to changes in drug plasma concentration-time profiles, appropriate 
testing in humans may have to be carried out, which can add much 
to the development costs of pharmaceutical formulations [2,10]. 
Very often, the in-vitro dissolution test is found to be more sensitive 
and discriminating than the in-vivo test. From a quality assurance 
point of view, a more discriminative dissolution method is preferred, 
because the test will indicate possible changes in the quality of the 
product before the in-vivo performance is affected [11]. 
The FTC was developed to answer some deficiencies perceived in 
other compendial techniques and offers a viable option for carrying 
out dissolution of various dosage forms such as tablets, powders, 
suppositories, hard gelatin capsules, implants, semisolids, and drug 
eluting stents [12-15]. This method has distinct advantages 
compared with the USP paddle and basket methods, especially for 
drugs with poor solubility and wettability [11,16], Powders with 
very low solubility and wettability present unique problems that 
necessitate optimized methods of sample loading into the FTC in 
order to achieve acceptable results [15]. The FTC dissolution 
apparatus is specially designed to have a small holdup volume 
compared with other USP dissolution apparatuses, which helps to 
minimize spreading of drug particles to undefined sites of the 
apparatus [15,17]. Moreover, FTC has several characteristics that 
can offer important information for the study of compounds and 
dosage forms including [18,19] (1) a built-in filtration system; (2) 
use as either an open-or closed-loop setup; (3) a high degree of 
automation; (4) sink condition can be maintained, due to the 
continuous flow of fresh medium and this feature is important for 
the study of poorly soluble drugs [15,19]; (5) ideal and controlled 
hydrodynamic conditions pumped either laminar (packed column) 
or turbulent flow mode for mild agitation, homogeneity, and 
definable flow. The hydrodynamics inside the FTC are not affected 
by media change and sampling, as can occur in traditional closed 
systems (i. e., rotating paddle apparatus, rotating basket apparatus) 
[15,16,19]; (6) dissolution medium and/or flow rate can be changed 
within a single run in order to mimic pH changes along GIT [20]; (7) 
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the possibility of changing the pH during the experiment, could be an 
alternative method for enteric coated dosage forms [21]; (8) the 
system can be used for the characterization of apparent dissolution, 
as samples (powder) can be placed in the cell without application of 
mechanical forces (i. e., compression) [17,19]; (9) development of 
IVIVC can be easier [22]; (10) several cell types are available for 
evaluation of different sample types and dosage forms, and (11) 
release from dosage forms over extended periods can be studied, as 
FTC eliminates the evaporation issue that can be observed with 
other apparatus [15,19].  
Few literature [11,15,17,23-29], discussed the optimization of the 
operational conditions of FTC affecting the release of drugs e. g. flow 
rate, the type of flow [laminar flow (packed column) or turbulent 
flow], cell size, gradient change of pH of the dissolution medium, 
operation of the FTC as a closed or open loop setup and the position 
of the dosage form in the dissolution cell.  
For IR formulations [23,30], many studies have shown that 
compendial in-vitro dissolution tests with Apparatus 2 make it 
difficult to show the differences among them. This is mainly related 
to the higher agitation level that causes the rapid disintegration of 
the tablet. The objective of this study is to evaluate the dissolution 
profiles of MX (practically water insoluble drug) from IR products 
available in the Egyptian market (7.5 mg/ product) using FTC (USP 
Apparatus 4) under variable operational conditions such as: cell size, 
type of flow, position of tablets within the FTC, different operational 
mode. Therefore, an optimum FTC design was proposed to predict 
MX dissolution from different pharmaceutical products.  
MATERIALS AND METHODS 
Materials 
Pure Meloxicam (MX) was kindly donated from Delta Pharma, Cairo, 
Egypt. All products used in this study were immediate release MX 
available in an Egyptian market, each contain 7.5 mg MX / products 
and all tests were performed within product expiration dates. 
Innovator reference product R was Mobic®
Generic product G1 was Mobitil
 tablets, obtained from 
Boehringer Ingelheim, Germany (batch number 905340).  
® tablets, MUP, Egypt (batch number 
92054); G2 was Mexicam® tablets, Delta Pharma, Egypt (batch 
number 80815); G3 was Melocam® tablets, Amoun Pharmaceutical 
Co., Egypt (batch number 90434); G4 was Moxen® tablets, EGPI, 
Egypt (batch number 90034); G5 was Anti-CoxІІ®
A standard curve ranging from 0.4 to 30 µg/mL in phosphate buffer 
(pH 7.5) was constructed [
 capsules, Adwia 
Co., Egypt (batch number 81051). Sodium hydroxide pellets and 
Potassium dihydrogen orthophosphate were purchased from 
Laboratory Rasayan, India. Methanol (HPLC grade, Prolabo, France) 
was used for stock solution preparation. Milli-Q purified water 
(Millipore Corp., Billerica, MA, USA) was used to prepare the 
dissolution medium. 
Methods 
Analysis of MX 
31]. A stock solution was prepared by 
dissolving 5 mg of MX powder in 50 mL methanol to yield a 
concentration of 100 µg/mL.  This solution was serially diluted with 
phosphate buffer of pH 7.5 to yield the desired concentration range. The 
absorbance of the prepared solutions was measured 
spectrophotometrically (DU–650 UV-Vis spectrophotometer, Beckman, 
USA) at predetermined λmax
The comparative in-vitro dissolution studies of 6 different IR market 
products (each contained 7.5 mg MX); one reference product (R) and five 
generic products (G1-G5) were carried out using the open loop setup of 
FTC [ USP Apparatus 4, a Dissotest CE-6 equipped with a CY 7-50 piston 
pump (Sotax, Switzerland)]. Each tablet was placed into the large 
dissolution cell (22.6 mm diameter) according to the cell design shown 
in fig. 1 Pattern-A. A Built-in filtration system with 0.7-µm What man 
glass micro-fiber (GF/F and GF/D) and glass wool was used throughout 
the study. Dissolution medium was filtered degassed phosphate buffer 
(pH 7.5) maintained at 37.0 ± 0.5 °C, pumped at 8 ± 0.2 mL/min. The 
dissolution studies were carried-out in triplicate. Sample fractions were 
collected at the following time intervals 10, 20, 30, 45, 60, 90, 120, 150 
and 180 min. and analyzed by UV/spectro photometric method at 363 
nm against phosphate buffer pH 7.5 as blank. 
The dissolution profiles of the five tested products of MX were 
compared with the innovator R using similarity factor (ƒ
 of 363 nm against the phosphate buffer of 
pH 7.5 as blank. The absorbance was plotted against the concentration, 
and the response factor was calculated. Each concentration was analyzed 
in triplicate, and the mean values were calculated. A linear zero-intercept 
relationship was established, where the slope and regression coefficient 
was 0.0589 and 0.9998, respectively. Percent recoveries ranged from 
96.32% to 113.75%, and the average response factor was 16.639 ± 
1.045. 
Comparative in-vitro dissolution study of MX products 
2
For comparing the dissolution profiles of different MX market products, 
the similarity factor (ƒ
) and 
dissolution efficiency (D. E.). 
Similarity Factor 
2 32) as proposed by Moore and Flanner [ ] was 
calculated from the mean dissolution data and was used to compare 
between different FTC designs. (ƒ2 5) is defined by FDA [ ] as  
ƒ2
Where n is the number of time points collected during the in-vitro 
release test, R
 = 50 x log {[1+ (1/n) Σt=1n (Rt – Tt) 2]-0.5 x 100} 
t and Tt are the cumulative percentages release at the 
selected (n) time point of the two tested formulae. The (ƒ2) value is a 
measure of the similarity between two dissolution profiles and its value 
ranges from 0 and 100. FDA has set a public standard of (ƒ2
5
) value of 50-
100 to indicate similarity between two dissolution profiles [ ,32,33]. 
Dissolution efficiency 
This concept was proposed by Khan and Rhodes in 1975 [34] and is 
defined as follows:  
D. E. = 0∫ PtP y × dt × 100 yR100R × t 
Dissolution efficiency (D. E.) was calculated from the area under the 
dissolution curve at time (t), measured using the trapezoidal rule, 
and expressed as percentage of the area of the rectangle described 
by 100% dissolution, yR100R, in the same time [35,36]. 
Study of different FTC designs on dissolution of MX from IR 
products:  
The dissolution profile of one selected generic product (G1) was 
compared to the reference product R using different cell designs (fig. 
1, Patterns A-D), as follows:  
Pattern-A: Large dissolution cell (22.6 mm), laminar flow (packed 
column, glass beads fill the entry cone), free tablet position. 
Pattern-B: Small dissolution cell (12 mm), laminar flow (packed 
column, glass beads fill the entry cone), free tablet position. 
Pattern-C: Small dissolution cell (12 mm), turbulent flow. 
Pattern-D: Large dissolution cell (22.6 mm), laminar flow (packed 




Fig. 1: Schematic diagrams showing the four patterns for MX 
tablet loaded into the FTC 
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Study of the open and closed loops setup of the FTC on 
dissolution of MX from IR products:  
The FTC was operated either: (1) as an open loop setup with fresh 
solvent from the reservoir continuously passes through the cell or 
(2) as a closed loop setup, where a fixed volume of solvent is 
recycled. For operation of FTC dissolution apparatus in the open 
loop setup; fresh dissolution medium (phosphate buffer pH 7.5) was 
pumped continuously and sample fractions were collected at the 
following time intervals 10, 20, 30, 45, 60, 90, 120 min. While, for the 
closed loop setup, 900 mL phosphate buffer (pH 7.5) was recycled, 
10 mL samples were collected at the specified time intervals and 
were replaced by the same volume of the fresh dissolution medium. 
This factor was studied for R and G1 using Pattern-C (fig. 1). 
RESULTS AND DISCUSSION 
MX, a non steroidal anti-inflammatory drug, was used as water 
insoluble model drug in this study. It is indicated for short term 
symptomatic treatment of exacerbations of osteoarthrosis as well as 
long term symptomatic treatment of rheumatoid arthritis or 
ankylosing spondylitis [37,38].  
MX is an acidic drug (pKa, 1.1), practically insoluble in water at 
physiological pH (12 µg/mL) and has a zwitterionic property with 
two pKa values (pKa1 =1.09, pKa2 =4.18) [39,40]. The percentage of 
ionized drug and the solubility increase with increasing pH until the 
highest solubility reported is reached in phosphate buffer pH 10, 
decreasing pH leads to an increase in the ratio of non-ionized to 
ionized drug combined with a decrease in solubility [39]. Previous 
pharmacokinetics studies have shown that MX has prolonged 
absorption with T max
41
 of longer than 5h, indicating the slow 
absorption of MX after an oral administration [ ,42]. In most 
studies, the dissolution of MX is carried out in phosphate buffer of 
pH 7.5.  
In this study, the dissolution tests were carried-out using either the 
open or the closed loops setup of the FTC. When the system operates 
in the open loop setup, the data collected represents the amount 
dissolved/released at specific time intervals (estimate of dissolution 
rate) and is non cumulative form [19,43]. Data can be transformed to 
the cumulative form; in this case, any mistakes associated with the 
estimation of the total drug released during a specific time interval 
will be transferred to the next time interval. If a model is to be fitted 
to the data, by converting them to the cumulative form, the 
fundamental assumption of independence of errors is violated 
[18,19]. Data collected when the system operates in the closed loop 
setup is in cumulative form. 
Comparative in-vitro dissolution study of MX products 
Fig. 2 showed the percent of MX dissolved from the generic products 
(G1-G5) versus the innovator product (R) using the open loop setup 
of the FTC. The FTC was operated using large cell at laminar flow 
(free tablet position); as illustrated in Pattern-A (fig. 1). The 
dissolution profiles of the five generic products showed different 
behaviors, and could be divided into two classes. Class I (G3 and G4) 
and Class II (G1, G2 and G5). After 30 min, Class I showed higher 
percent of MX dissolved (82.636%, 90.521% and 87.231% for R, G3 
and G4, respectively) and Class II showed lower percent of MX 
dissolved than the acceptance criterion in the USP and the 
requirement for an IR dosage form (61.168%, 43.220% and 
56.082% for G1, G2, G5, respectively). Although, the dissolution study 
period was extended up to 180 min, however, the products of Class II 
did not show a pronounced increase in % MX dissolved. Meanwhile, in 
a previous study using large cell [11], it was found that the reference 
products of diclofenac sodium SR tablets (Voltaren 100 mg) 
manufactured in two different manufacturing sites (Novartis-Egypt, 
Novartis-Switzerland), showed remarkable differences in the release 
rate of diclofenac sodium SR. This might open a question about the 
performance of the two products in-vivo [44]. 
The dissolution profiles of the 5 generic products were compared with 
the innovator R using the similarity factor ƒ2. Fig. 3 showed the ƒ2 results 
with the following values 33, 25, 56, 50 and 35 for G1, G2, G3, G4 and G5, 
respectively. The ƒ2 values of G3 and G4 products were found to be 
within the FDA acceptance limit (50-100). These values revealed that 
Class I had a similar dissolution profiles to R, while the Class II revealed 
dissimilar dissolution profiles. In this respect, we could conclude that the 
two Classes might give different data in-vivo. 
 
 
Fig. 2: Dissolution profiles of MX from IR products (7.5 mg MX / 










Fig. 3: Comparison between dissolution profiles of different MX 
generic products (G1 – G5) versus R (Mobic®) expressed by 
similarity factor "ƒ2
The dissolution efficiency (D. E.) was calculated for each individual 
cell, and hence, the mean D. E. for each product with its 95% 
confidence intervals (C. I.) was compared by measuring the 
difference between the mean D. E. and confidence intervals of the 
innovator product and the tested products [
". 
 
36]. If the differences of 
the mean dissolution efficiencies as well as the 95% confidence 
intervals are within appropriate limits (±10%), one can conclude 
that the dissolution profiles of the reference and test are equivalent 
[36]. As shown in table 1, both conditions have been satisfied only 
for two products, G3 and G4. The values of the mean D. E. Were 
found to be within the appropriate limits; D. D. E. were 7.18 and 1.76 
and D. C. I. were 6.93 and 5.75 (±10%) for G3 and G4, respectively. 
Therefore, the dissolution profiles of G3 and G4 were similar with 
each other and with the innovator as per these methods.  
Therefore, and according to the calculated ƒ2
Tested products 
 as well as D. E., it could 
be concluded that the two generic products G3 and G4 might 
probably be interchangeable with each other and with the innovator 
product R. However, product G1, G2 and G5 might not be 
interchangeable with the innovator. 
 
Table 1: Mean dissolution efficiencies with 95% confidence 
intervals 
Mean D. E. (%) with C. I. D. D. E. D. C. I. 
R (Mobic®) 81.51 (75.57, 87.44) 0 0 
Mobitil (G1) 59.18 (54.69, 63.67) 22.33 32.75 
Mexicam (G2) 58.20 (54.32, 62.03) 23.31 33.12 
Melocam (G3) 88.69 (80.51, 96.87) 7.18 6.93 
Moxen (G4) 83.27 (81.69, 84.85) 1.76 5.75 
Anti-Cox (G5) 70.55 (62.30, 78.79) 10.96 25.14 
D. E.: Dissolution Efficiency, C. I.: Confidence Intervals, D. D. E.= 
Difference of the mean D. E. between the innovator and the tested 
product, D. C. I. Difference in confidence intervals and is calculated 
Emara et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 11, 254-260 
257 
by considering the maximum possible mean D. E. value of Innovator 
and minimum possible mean D. E. value of other products. 
The FDA provides guidelines for dissolution tests for oral IR dosage 
forms, but also realizes the need for individualizing the method on a 
case by case basis leaving the justification of a given methodology up 
to the scientist. Therefore, the individual scientist is challenged to 
design an appropriate test based on the objectives to be accomplished, 
e. g., quality control, IVIVC, showing bioequivalence, etc.  
Therefore, we proposed other FTC features to investigate possible 
dissolution similarity or dissimilarity between R and a selected 
generic product from Class II, that might affect the final judgment. 
G1 was selected on the basis that it exhibited dissimilar dissolution 
profile versus R (ƒ2
Fig. 4 showed the dissolution profiles of MX obtained from studying 
the effect of the cell size of 12.0 and 22.6 mm on the amount of MX 
dissolved from R and G1 using the open loop setup (c. f. Fig. 1, 
Patterns-A & B for cell designs). Different cell sizes showed small 
differences on MX dissolution rate from R (fig. 4A). Where the 
percent of MX dissolved after 30 min was 79.15% and 82.64% and 
after 1 h was 85.89% and 86.20% from the small and large cells, 
respectively. The ƒ
=33). Four different patterns (A-D) were 
investigated using G1 versus R.  
Effect of cell size 
2
11
 value between the two dissolution data was 64 
indicating similar dissolution profiles obtained from the two 
patterns. Similarly, in a previous study done by Emara et al. [ ], 
there was also no difference in the release rate of diclofenac sodium 
from Voltaren®
On the other hand, the dissolution rate of MX from G1 using the two 
cells (large, small) showed remarkable difference, i. e. dissimilar 
dissolution profiles within the product with ƒ
 100 mg SR tablets (Novartis-Switzerland), upon 
using either the small or large cell. The authors attributed their 
result to the fact that the saturation concentration of diclofenac 
sodium was rather high to be affected by the cell size. 
2
26
 value of 27 (fig. 4B). 
The percent of MX dissolved from G1 after 30 min was 90.19%, and 
61.17%, and remained constant up to 2 h from the small and large 
cell, respectively. Similar results were published previously 
[ ,27,45,46], a study by Cammarn et al. [26], showed that the 
dissolution rates of salicylic acid in large cell were significantly 
lower than those seen in small cells, moreover, the dissolution rate is 
insensitive to flow rate in these larger cells. Another study by Bielen 
et. al. [27] reported that the dissolution rates of salicylic acid and 
prednisone tablets in the large cell were significantly lower than 
those in the small cell.  
 
 
Fig. 4: Effect of cell size on the dissolution rate of MX using the 
open loop setup of FTC: (A) Mobic®, R; (B) Mobitil®
Also, in another study [
, G1 (for cell 
design see Patterns-A & B). 
45], the release rates of nifedipine controlled-
release product in the large cell were significantly lower than those 
in the small cell. Wu et al. [46], reported that the dissolution rates of 
theophylline and naproxen tablets in the large cell were significantly 
lower than those in the small cell at flow rate 8 mL/min. The results 
indicated that as the diameter of cell increased, the Reynold’s 
number [47] and the mean dissolution rate decreased, hence, the 
small cell gave higher dissolution than the larger cell and these 
results were observed for both theophylline, (high solubility) and 
naproxen (low solubility) [46]. Emara et al. [11] reported that, in the 
small cell the fresh dissolution medium is recirculated faster, and the 
concentration of a given drug in the diffusion layer around the tablet 
is affected by the concentration gradient. This gives rise to more 
drug diffusion, which is expected to increase the amount of drug 
released. 
Upon comparing the dissolution similarity between G1 versus R (i. e. 
between products), it was found that ƒ2  values were 37 and 33 using 
small and large cells, respectively, which indicated dissolution 
dissimilarity between G1 and R under these operational conditions.  
It is worthy to point out here that although the two products (R & 
G1) contain the same drug in the same dosage from (IR), however, 
the two products behave differently with regard to the cell size. In 
this respect, we could conclude that the two products might give 
different in-vivo data. 
Effect of type of flow 
Fig. 5 showed the effect of turbulent versus laminar flow (free tablet 
position) on the amount of MX dissolved from R and G1 using the 
open loop setup (cf. Fig. 1, Patterns-B & C for cell design). The type of 
flow had almost no effect on MX dissolution rate from R (fig. 5A), 
where the ƒ2  value was 69 indicating similarity between the two 
types of flow. The percent of MX dissolved was 79.15% and 73.82% 
in 30 min and after 1h was 85.89% and 82.05% for the laminar and 
turbulent flow conditions, respectively. On the other hand, the 
amount of MX dissolved from G1 increased pronouncedly upon 
applying laminar flow condition (fig. 5B). Where the percent of MX 
dissolved from G1 was found to be 93.09% and 81.12% in 30 min 
and remained constant up to 2 h when the laminar and turbulent 
flow were applied, respectively. The ƒ2  value was 43 which indicated 





Fig. 5: Effect of type of flow on the dissolution rate of MX using 
the open loop setup of FTC; (A) Mobic®, R; (B) Mobitil®, G1 (for 
cell design see Patterns-B & C). 
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Upon comparing the dissolution similarity between G1 versus R (i. e. 
between products), using the same FTC operational feature, it was 
found that ƒ2
Similarly, Morihara et al. [
 values were 37 and 48 when laminar flow and 
turbulent flow was applied, respectively, which indicated dissolution 
dissimilarity between G1 and R under these operational feature. 
28] studied the dissolution of salicylic acid 
from USP calibrator tablets and reported that the dissolution rate 
was higher when the tablet rest on top of the glass beads (i. e., 
laminar flow) than leaving the tablet free in the cell without glass 
beads. In another study [11], changing the type of flow had almost 
no effect on the amount of diclofenac sodium released from 
Voltaren® SR tablets. Thus, for each drug/product system, the 
optimum criteria, features and conditions of the FTC should be 
considered precisely to discriminate between different products and 
detect any minor change of excipients or manufacturing site of the 
product, which might give different in-vivo results.  
Effect of tablet position 
The effect of tablet position within the glass beads as well as the 
amount of glass beads loaded in the FTC using open loop setup (fig. 
1, Patterns-A & D) was demonstrated in fig. 6. It was found that the 
dissolution of MX from R and G1 were much lower when the tablet 
was buried in the glass beads than when the tablet rest on top of 
glass beads, the percent of MX dissolved after 30 min from R was 
8.27% and 82.63% for the two tablet positions, respectively (fig. 6A). 
Also, for G1 after 30 min, the percent of MX dissolved was 3.66% and 
61.17% for the two tablet positions (Patterns-A & D), respectively, 
and remained constant up to 2 h (fig. 6B). The similarity factor ƒ2  for 
R was 9 indicating dissimilarity between the dissolution profiles 
within the product (fig. 6A). Also, ƒ2  for G1 was 13, indicating 
dissolution dissimilarity obtained from changing tablet position 





Fig. 6: Effect of different tablet position on the dissolution rate 
of MX using the open loop setup of FTC: (A) Mobic®, R; (B) 
Mobitil®, G1 (for cell design see Patterns-A & D). 
 
Upon comparing the dissolution similarity between G1 versus R (i. e. 
between products), using the same FTC operational feature, it was 
found that ƒ2
The increase in the dissolution rate of the free tablet position 
(Pattern-A) might be due to the movement of the tablet. As long as 
the saturated aqueous layer surrounding the tablet changed faster, 
in the free position, this will create another fresh unsaturated layer 
which led to observed increase in MX dissolution rate [
 values were 48 and 33 using embedded tablet position 
(Pattern-D) and free tablet position (Pattern-A), respectively, which 
indicated dissolution dissimilarity between G1 and R under these 
operational feature.  
45]. 
These results were similar to previous studies [11,45]. Emara et al. 
[11] reported that the release rate of diclofenac sodium from SR 
tablets was significantly lower when the tablet was buried in the 
glass beads than placed on the top of the glass beads. Also, it was 
found that the release of nifedipine was decreased when the tablet 
was embedded in the glass beads [45]. However, a study carried out 
by Morihara et al. [28] showed that, the dissolution of salicylic acid 
from USP calibrator tablets was the highest when the tablet was 
buried in the glass beads, followed by placement on top of glass 
beads. These variable results between salicylic acid [28] in one hand 
and diclofenac sodium, nifedipine [11,45] and our current study on 
MX in the other hand, might throw light or open a door for the 
importance of optimizing all the operational conditions of the FTC to 
obtain reliable, reproducible results and eliminate any erratic 
dissolution data that could be occurred when the method was not 
properly adjusted. 
Effect of the open and closed loops setup  
The FTC apparatus can operate in two different modes: (1) as an 
open loop setup with fresh solvent from the reservoir continuously 
passes through the cell and (2) as a closed loop setup where a fixed 
volume of liquid is recycled. The open setup is selected for samples 
that require high volume of media (i. e., low solubility compounds), 
and the closed loop setup is selected when a low volume of medium 
is required [19]. 
Fig. 7 showed the effect of open and closed loops setup of the FTC on 
the amount of MX dissolved from R and G1 using Pattern-C (fig. 1). It 
was found that, the amount of MX dissolved was slightly increased 
on applying the closed loop setup (fig. 7 A & B) for both R and G1. In 
case of R, the percent of MX dissolved after 30 min was 73.82% and 
84.75% and after 1 h was 82.05% and 90.27% when the open and 
closed loops setup were applied, respectively (fig. 7A). For G1, the 
percent of MX released after 30 min was 81.12% and 94.72% and 
after 1 h was 82.15% and 94.72% for open and closed loops setup, 
respectively (fig. 7B). The similarity factor ƒ2 for R was 47 indicating 
dissimilarity between the dissolution profiles within the product 
(fig. 7A). Also, ƒ2  for G1 was 46, indicating dissolution dissimilarity 




Fig. 7: Effect of the open and closed loops setup of FTC on the 
dissolution rate of MX: (A) MobicP®P, R; (B) MobitilP® P, G1 (for cell 
design see Pattern-C). 
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Fig. 8 comparing the dissolution similarity between G1 versus R (i. e. 
between products), upon using the same FTC operational feature in 
each case, it was found that only the closed loop setup gave ƒ2  value 

















 value for the open loop setup was 48. Therefore, the 
closed loop setup gave similar dissolution profiles for G1 and R. 
 
 
Fig. 8: Comparison between dissolution profiles of MX products 
(G1 against R) expressed by similarity factor "ƒ2" at different 
FTC operational conditions. 
 
Based on these results, it is better to use the closed loop setup as to 
save time and chemicals used to prepare the dissolution medium as 
well as provide the simpler test procedure and less time consumed 
for the pre-filtration step. Where each cell requires a volume of 900 
mL or 1500 mL of dissolution medium for closed and open loop 
setup, respectively. A study done by Qiu et al. [23], to compare the 
dissolution profiles of paracetamol tablets (using the closed and 
open loops at three different flow rates of 4, 8 and 16 mL/min) 
showed similar dissolution profiles in both open and closed loops 
setup. All of the similarity factor ƒ2  values at different flow rates are 
greater than 50, indicating their similarity.  
Fig. 9 summarized the effect of different FTC operational conditions 















 values. It was worthy to mention that the 
dissolution profile of MX from R was highly affected by changing the 
tablet position, slightly affected by the open and closed loops setup 
and not affected by cell size and type of flow. On the other hand, the 
dissolution profile of MX from G1 was affected by all the previous 
operational conditions.  
 
 
Fig. 9: Effect of FTC operational conditions on the dissulotion 
profiles within each MX product (R or G1) expressed as 
Similarity factor " ƒR2R". 
 
CONCLUSION 
This study opens an important question about the optimization of 
the FTC to obtain reliable and discriminative results reflecting the 
major as well as the minor formulation variables prior to the 
bioequvilance testing. Upon applying specific and well controlled 
conditions of the FTC, it was found that the generic products 
MelocamP®P (G3) and MoxenP®P (G4), showed dissolution similarity 
compared to the innovator (MobicP® P).  
The in-vitro testing was extended to focus on other FTC operational 
conditions and its impact on the similarity / dissimilarity between 
the selected product G1 and R. The calculation of ƒR2R values for R and 
G1 upon applying different conditions of FTC, revealed that a one 
single in-vitro dissolution test out of seven, gave similar dissolution 
profiles (Pattern-C with closed loop setup). Moreover, the 
dissolution rate of product R was much less affected by changing the 
FTC operational conditions than product G1. 
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